<p>Orforglipron (also known as Foundayo) is one of the most promising drugs in the GLP-1 space, notably as only the second oral GLP-1 option for obesity. Unlike injectable treatments, it does not require refrigeration and is easier to scale for widespread use. </p><p>Dave highlights the ongoing questions that linger about the drugs approval as it relates to liver safety.</p>